Vast Majority in US Remain Susceptible to COVID-19: Study

Fewer than 1 in 10 dialysis patients sampled had antibodies against the novel coronavirus as of July, indicating that the greater population is far from levels required to achieve herd immunity.

Written byMax Kozlov
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM,
PICSFIVE

Fewer than 10 percent of dialysis patients sampled in the US showed signs of having had COVID-19 as of late July, a sign that much of the population remains susceptible to the novel coronavirus, according to one of the largest studies of its kind published Friday (September 25) in The Lancet.

Researchers studied the prevalence of antibodies against SARS-CoV-2 in a random subset of thousands of dialysis patients across the country. Their findings do not indicate exactly how many in the US are immune to the virus, as it is unclear how long immunity lasts and not every infected individual develops antibodies.

“We are still in the middle of the fight,” Eli Rosenberg, an epidemiologist at the State University of New York at Albany who was not part of the study, tells The Washington Post. “We’re all tired, and we’re all hoping for a vaccine. This shows ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Max is a science journalist from Boston. Though he studied cognitive neuroscience, he now prefers to write about brains rather than research them. Prior to writing for The Scientist as an editorial intern in late 2020 and early 2021, Max worked at the Museum of Science in Boston, where his favorite part of the job was dressing in a giant bee costume and teaching children about honeybees. He was also a AAAS Mass Media Fellow, where he worked as a science reporter for the St. Louis Post-Dispatch. Read more of his work at www.maxkozlov.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies